Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
TILT Biotherapeutics Ltd.
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Essen Biotech
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University of Pittsburgh
Case Comprehensive Cancer Center
Thomas Jefferson University
The Netherlands Cancer Institute
Centre Hospitalier Universitaire Vaudois
Vall d'Hebron Institute of Oncology
National Cancer Institute (NCI)
University of Kansas Medical Center
BioEclipse Therapeutics
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
Fate Therapeutics
University of Pennsylvania
Fate Therapeutics
The Christie NHS Foundation Trust
BGI, China
BGI, China
Sheba Medical Center
National Institutes of Health Clinical Center (CC)
Karolinska University Hospital
Genocea Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Mie University
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center